BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Biodexa Pharmaceuticals Plc
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026
$0.39−0.07 (-14.36%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2022 Ended Jun 30, 2022 | Sep 14, 2022 | Before market open | – | – | – |
Press releases
Announcements Biodexa Pharmaceuticals filed with the SEC
Biodexa Enters Into Warrant Exercise Transaction
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa”
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Result of Annual General Meeting
EX-99.1 to Form 6-K
Biodexa Announces Pricing of $3.5 Million Registered
EX-99.1 to Form 6-K
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or
EX-99.1 to Form 6-K
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a
EX-99.1 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
EX-99.4 to Form 6-K
EX-99.4 to Form 6-K
Preliminary Results for the Year Ended 31 December 2025
EX-99.1 to Form 6-K
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a
EX-99.1 to Form 6-K
a potent Phase 1 ready
EX-99.1 to Form 6-K
of $10 Million Public Offering
EX-99.1 to Form 6-K
Biodexa Announces Approval of CTA in Europe
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
ADSs Outstanding Post Ratio Change
EX-99.1 to Form 6-K
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an
EX-99.1 to Form 6-K
(“ Biodexa ” or the “ Company ”)
EX-99.1 to Form 6-K
and registered in England and Wales with registered no. 09216368)
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
EX-99.4 to Form 6-K
EX-99.4 to Form 6-K
(Incorporated and registered in England and Wales with registered
EX-99.1 to Form 6-K
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a
EX-99.2 to Form 6-K
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
EX-99.1 to Form 6-K
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a
EX-99.1 to Form 6-K
The Board of Directors is proposing three resolutions:
EX-99.1 to Form 6-K
England and Wales with registered no. 09216368)
EX-99.2 to Form 6-K
or the “Company” or, together with its subsidiaries, the “Group”)
EX-99.1 to Form 6-K